Compare WF & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WF | NBIX |
|---|---|---|
| Founded | 1899 | 1992 |
| Country | South Korea | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.5B | 15.5B |
| IPO Year | 2003 | 1996 |
| Metric | WF | NBIX |
|---|---|---|
| Price | $73.63 | $153.96 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 22 |
| Target Price | N/A | ★ $180.91 |
| AVG Volume (30 Days) | 72.4K | ★ 1.4M |
| Earning Date | 04-24-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.71% | N/A |
| EPS Growth | N/A | ★ 41.95 |
| EPS | N/A | ★ 3.30 |
| Revenue | N/A | ★ $161,626,000.00 |
| Revenue This Year | $18.73 | $24.73 |
| Revenue Next Year | $4.33 | $13.14 |
| P/E Ratio | ★ $9.03 | $47.25 |
| Revenue Growth | N/A | ★ 977.51 |
| 52 Week Low | $48.83 | $122.14 |
| 52 Week High | $84.71 | $186.12 |
| Indicator | WF | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 66.23 | 42.55 |
| Support Level | $66.20 | $152.67 |
| Resistance Level | $74.83 | $161.29 |
| Average True Range (ATR) | 1.29 | 3.72 |
| MACD | 0.04 | 0.28 |
| Stochastic Oscillator | 100.00 | 41.35 |
Woori Financial Group Inc is a banking and financial services holding company that offers a wide range of businesses, including corporate banking, consumer banking, credit card operations, investment banking, capital markets activities, international banking, asset management, life insurance, and other businesses. It provides products and services to customers, which mainly comprise small- and medium-sized enterprises and individuals, as well as some of Korea's corporations. It has six operational business segments: banking, life insurance, credit card, capital, investment securities, and other operations.
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.